Skip to main content
Top
Published in: Nutrition Journal 1/2011

Open Access 01-12-2011 | Research

Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: A cross-sectional study

Authors: Jinyan Zhao, Yunpeng Zhao, Hao Wang, Xing Gu, Jun Ji, Chunfang Gao

Published in: Nutrition Journal | Issue 1/2011

Login to get access

Abstract

Background

Previous studies suggested that the abnormality of metabolism is a newly identified risk factor in HBV-related hepatocellular carcinoma (HCC). The association between metabolic factors and hepatocellular carcinoma (HCC) has not been clarified up to now. This study was conducted to investigate the prevalence of metabolic abnormalities in HCC and to probe the association between metabolic parameters and liver function as well, so as to evaluate the interactions between metabolism and the development of HBV-related HCC.

Methods

Totally 179 cases of HBV-related HCC, who were surgically treated and pathologically confirmed were enrolled. HBV carriers (n = 100) and healthy controls (n = 150) were recruited from routine physical examination during the same period. Body mass index (BMI) was obtained from medical documentation. All the metabolic-related parameters and liver function tests were determined with routine biochemical or immunological analytic methods. Malondialdehyde (MDA) and total antioxidant capacity(TAOC)were detected by chemical analytic methods. A stratified analysis was conducted according to BMI, glycated albumin (GA), free fatty acids (FFA), and the relationships between the metabolic-related parameters and liver functions were analyzed in HCC and control subjects.

Results

HCC group showed significantly high levels of mean BMI, serum glucose, low serum lipids levels than controls (P < 0.05). Acquired by stratified analysis, the higher the BMI, the higher level of insulin and homeostasis model assessment for insulin resistance (HOMA-IR) (P < 0.01) were found in HCC patients. Elevated level of MDA and γ-glutamyltransferase (GGT) were revealed in those with high serum FFA level for the first time. Strong associations between metabolic factors and liver function were shown in HCC (P < 0.05). Higher GA level was strongly associated with increased risk of cancer compared to healthy controls (OR = 9.87, 95% confidence interval: 1.86~52.29). Serum triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) levels were negative contributory factors for HCC (OR = 0.05, 95% confidence interval: 0.01~0.27 and OR = 0.32, 95% confidence interval, 0.11~0.95: respectively).

Conclusions

Metabolic abnormalities are closely associated with the occurrence and development of HBV-related HCC. Oxidative stress and/or lipid peroxidation might be involved in the pathogenesis and acceleration of liver function impairments in HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2 (9): 533-543. 10.1016/S1470-2045(01)00486-7.CrossRefPubMed Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2 (9): 533-543. 10.1016/S1470-2045(01)00486-7.CrossRefPubMed
2.
go back to reference Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008, 14 (27): 4300-4308. 10.3748/wjg.14.4300.CrossRefPubMedPubMedCentral Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD: Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008, 14 (27): 4300-4308. 10.3748/wjg.14.4300.CrossRefPubMedPubMedCentral
3.
go back to reference Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009, 58 (1): 111-117. 10.1136/gut.2008.157735.CrossRefPubMed Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL: Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009, 58 (1): 111-117. 10.1136/gut.2008.157735.CrossRefPubMed
4.
go back to reference Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005, 365 (9468): 1415-1428. 10.1016/S0140-6736(05)66378-7.CrossRefPubMed Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005, 365 (9468): 1415-1428. 10.1016/S0140-6736(05)66378-7.CrossRefPubMed
5.
go back to reference Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50 (8): 1844-1850. 10.2337/diabetes.50.8.1844.CrossRefPubMed Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50 (8): 1844-1850. 10.2337/diabetes.50.8.1844.CrossRefPubMed
6.
go back to reference Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009, 50 (1): 204-210. 10.1016/j.jhep.2008.10.010.CrossRefPubMed Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009, 50 (1): 204-210. 10.1016/j.jhep.2008.10.010.CrossRefPubMed
7.
go back to reference Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epide miology of fatty liver. Eur J Gastroenterol Hepatol. 2004, 16 (11): 1087-1093. 10.1097/00042737-200411000-00002.CrossRefPubMed Bellentani S, Bedogni G, Miglioli L, Tiribelli C: The epide miology of fatty liver. Eur J Gastroenterol Hepatol. 2004, 16 (11): 1087-1093. 10.1097/00042737-200411000-00002.CrossRefPubMed
8.
go back to reference Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002, 36 (6): 1349-1354.CrossRefPubMed Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002, 36 (6): 1349-1354.CrossRefPubMed
9.
go back to reference Jo SK, Lee WY, Rhee EJ, Won JC, Jung CH, Park CY, Oh KW, Park SW, Kim SW: Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta. 2009, 403 (1-2): 234-240. 10.1016/j.cca.2009.03.035.CrossRefPubMed Jo SK, Lee WY, Rhee EJ, Won JC, Jung CH, Park CY, Oh KW, Park SW, Kim SW: Serum gamma-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clin Chim Acta. 2009, 403 (1-2): 234-240. 10.1016/j.cca.2009.03.035.CrossRefPubMed
10.
go back to reference Kasapoglu B, Turkay C, Bayram Y, Koca C: Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res. 2010, 132: 56-61.PubMed Kasapoglu B, Turkay C, Bayram Y, Koca C: Role of GGT in diagnosis of metabolic syndrome: a clinic-based cross-sectional survey. Indian J Med Res. 2010, 132: 56-61.PubMed
11.
go back to reference Yuen MF, Hou JL, Chutaputti A: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009, 24 (3): 346-353. 10.1111/j.1440-1746.2009.05784.x.CrossRefPubMed Yuen MF, Hou JL, Chutaputti A: Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009, 24 (3): 346-353. 10.1111/j.1440-1746.2009.05784.x.CrossRefPubMed
12.
go back to reference Sobin LH, Wittekind CL, eds: TNM classification of malignant tumors. 2002, New York: Wiley, 6 Sobin LH, Wittekind CL, eds: TNM classification of malignant tumors. 2002, New York: Wiley, 6
13.
go back to reference Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002, 36 (4): 543-546. 10.1016/S0168-8278(02)00004-1.CrossRefPubMed Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002, 36 (4): 543-546. 10.1016/S0168-8278(02)00004-1.CrossRefPubMed
15.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18 (6): 499-502.PubMed
16.
go back to reference Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85 (7): 2402-2410. 10.1210/jc.85.7.2402.CrossRefPubMed Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85 (7): 2402-2410. 10.1210/jc.85.7.2402.CrossRefPubMed
17.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28 (7): 412-419. 10.1007/BF00280883.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28 (7): 412-419. 10.1007/BF00280883.CrossRefPubMed
18.
go back to reference Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 109 (3): 433-438. 10.1161/01.CIR.0000111245.75752.C6.CrossRefPubMed Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 109 (3): 433-438. 10.1161/01.CIR.0000111245.75752.C6.CrossRefPubMed
19.
go back to reference Opie LH: Metabolic syndrome. Circulation. 2007, 115 (3): e32-35. 10.1161/CIRCULATIONAHA.106.671057.CrossRefPubMed Opie LH: Metabolic syndrome. Circulation. 2007, 115 (3): e32-35. 10.1161/CIRCULATIONAHA.106.671057.CrossRefPubMed
20.
go back to reference Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S: Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009, 20 (5): 741-750. 10.1007/s10552-008-9287-6.CrossRefPubMed Inoue M, Kurahashi N, Iwasaki M, Tanaka Y, Mizokami M, Noda M, Tsugane S: Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control. 2009, 20 (5): 741-750. 10.1007/s10552-008-9287-6.CrossRefPubMed
21.
go back to reference Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009, 49 (3): 851-859. 10.1002/hep.22734.CrossRefPubMed Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009, 49 (3): 851-859. 10.1002/hep.22734.CrossRefPubMed
22.
go back to reference Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S97-103.CrossRefPubMed Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM: Obesity and hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S97-103.CrossRefPubMed
23.
go back to reference Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005, 54 (4): 533-539. 10.1136/gut.2004.052167.CrossRefPubMedPubMedCentral Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005, 54 (4): 533-539. 10.1136/gut.2004.052167.CrossRefPubMedPubMedCentral
24.
go back to reference El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004, 126 (2): 460-468. 10.1053/j.gastro.2003.10.065.CrossRefPubMed El-Serag HB, Tran T, Everhart JE: Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004, 126 (2): 460-468. 10.1053/j.gastro.2003.10.065.CrossRefPubMed
25.
go back to reference Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A: Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res. 2008, 39 (8): 803-808. 10.1016/j.arcmed.2008.08.004.CrossRefPubMed Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A: Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res. 2008, 39 (8): 803-808. 10.1016/j.arcmed.2008.08.004.CrossRefPubMed
26.
go back to reference Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008, 135 (1): 111-121. 10.1053/j.gastro.2008.03.073.CrossRefPubMed Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008, 135 (1): 111-121. 10.1053/j.gastro.2008.03.073.CrossRefPubMed
27.
go back to reference Yu MC, Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S72-78.CrossRefPubMed Yu MC, Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004, 127 (5 Suppl 1): S72-78.CrossRefPubMed
28.
go back to reference Porepa L, Ray JG, Sanchez-Romeu P, Booth GL: Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010, 182 (11): E526-531.CrossRefPubMedPubMedCentral Porepa L, Ray JG, Sanchez-Romeu P, Booth GL: Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010, 182 (11): E526-531.CrossRefPubMedPubMedCentral
29.
go back to reference Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM: Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010, 16 (18): 2265-2271. 10.3748/wjg.v16.i18.2265.CrossRefPubMedPubMedCentral Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM: Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol. 2010, 16 (18): 2265-2271. 10.3748/wjg.v16.i18.2265.CrossRefPubMedPubMedCentral
30.
go back to reference Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 2006, 52 (4): 601-623. 10.1373/clinchem.2005.061408.CrossRefPubMed Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A: Biomarkers of oxidative damage in human disease. Clin Chem. 2006, 52 (4): 601-623. 10.1373/clinchem.2005.061408.CrossRefPubMed
31.
go back to reference Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O: Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis. 2005, 5: 95-10.1186/1471-2334-5-95.CrossRefPubMedPubMedCentral Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O: Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis. 2005, 5: 95-10.1186/1471-2334-5-95.CrossRefPubMedPubMedCentral
32.
go back to reference Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN, Chisari FV: Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA. 1994, 91 (26): 12808-12812. 10.1073/pnas.91.26.12808.CrossRefPubMedPubMedCentral Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN, Chisari FV: Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA. 1994, 91 (26): 12808-12812. 10.1073/pnas.91.26.12808.CrossRefPubMedPubMedCentral
33.
go back to reference Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE: Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci. 2007, 96 (1): 2-15.CrossRefPubMed Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE: Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci. 2007, 96 (1): 2-15.CrossRefPubMed
34.
go back to reference Sasaki Y: Does oxidative stress participate in the development of hepatocellular carcinoma?. J Gastroenterol. 2006, 41 (12): 1135-1148.CrossRefPubMed Sasaki Y: Does oxidative stress participate in the development of hepatocellular carcinoma?. J Gastroenterol. 2006, 41 (12): 1135-1148.CrossRefPubMed
35.
go back to reference Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ: Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008, 9 (8): 616-622. 10.1631/jzus.B0720016.CrossRefPubMedPubMedCentral Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ: Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008, 9 (8): 616-622. 10.1631/jzus.B0720016.CrossRefPubMedPubMedCentral
36.
go back to reference Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005, 54 (3): 603-608. 10.2337/diabetes.54.3.603.CrossRefPubMedPubMedCentral Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005, 54 (3): 603-608. 10.2337/diabetes.54.3.603.CrossRefPubMedPubMedCentral
37.
go back to reference Suh SY, Choi SE, Ahn HY, Yang HM, Kim YI, Sung NJ: The association between normal alanine aminotransferase levels and the metabolic syndrome: 2005 Korean National Health and Nutrition Examination Survey. Metabolism. 2009, 58 (12): 1731-1736. 10.1016/j.metabol.2009.05.028.CrossRefPubMed Suh SY, Choi SE, Ahn HY, Yang HM, Kim YI, Sung NJ: The association between normal alanine aminotransferase levels and the metabolic syndrome: 2005 Korean National Health and Nutrition Examination Survey. Metabolism. 2009, 58 (12): 1731-1736. 10.1016/j.metabol.2009.05.028.CrossRefPubMed
38.
go back to reference Sowa J-p, Penndorf V, Herzer K, Kaiser G, Ertle J, Deche A, Gerken G, Syn W-k, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International Journal of Cancer. 2011, 128: 2436-2443. 10.1002/ijc.25797.CrossRefPubMed Sowa J-p, Penndorf V, Herzer K, Kaiser G, Ertle J, Deche A, Gerken G, Syn W-k, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International Journal of Cancer. 2011, 128: 2436-2443. 10.1002/ijc.25797.CrossRefPubMed
39.
go back to reference Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection. Hepatology. 2011, 5: 1820-1832. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection. Hepatology. 2011, 5: 1820-1832.
40.
go back to reference Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH: A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection. Int J Obes. 2006, 1-6. Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH: A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection. Int J Obes. 2006, 1-6.
41.
go back to reference Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH: The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem. 2004, 279 (27): 28106-28112. 10.1074/jbc.M403176200.CrossRefPubMed Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH: The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem. 2004, 279 (27): 28106-28112. 10.1074/jbc.M403176200.CrossRefPubMed
42.
go back to reference Lee J, Song EY, Chung TW, Kang SK, Kim KS, Chung TH, Yeom YI, Kim CH: Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo A-I and Apo B. Arch Biochem Biophys. 2004, 426 (1): 18-31. 10.1016/j.abb.2003.12.039.CrossRefPubMed Lee J, Song EY, Chung TW, Kang SK, Kim KS, Chung TH, Yeom YI, Kim CH: Hyperexpression of N-acetylglucosaminyltransferase-III in liver tissues of transgenic mice causes fatty body and obesity through severe accumulation of Apo A-I and Apo B. Arch Biochem Biophys. 2004, 426 (1): 18-31. 10.1016/j.abb.2003.12.039.CrossRefPubMed
43.
go back to reference Michiel DF, Oppenheim JJ: Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol. 1992, 3 (1): 3-15.PubMed Michiel DF, Oppenheim JJ: Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol. 1992, 3 (1): 3-15.PubMed
44.
go back to reference Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH: Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006, 38 (9): 668-672. 10.1016/j.dld.2006.05.014.CrossRefPubMed Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH: Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006, 38 (9): 668-672. 10.1016/j.dld.2006.05.014.CrossRefPubMed
45.
go back to reference Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H: Serum total cholesterol and triglycerides levels in patients with lung cancer. Int JMol Med. 2000, 5 (2): 201-205. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H: Serum total cholesterol and triglycerides levels in patients with lung cancer. Int JMol Med. 2000, 5 (2): 201-205.
46.
go back to reference Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H: Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med. 2000, 6 (3): 307-311.PubMed Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H: Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med. 2000, 6 (3): 307-311.PubMed
47.
go back to reference Jiang Jingting, Nilsson-Ehle Peter, Xu Ning: Influence of liver cancer on lipid and lipoprotein metabolism. Lipids in Health and Disease. 2006, 5 (4): Jiang Jingting, Nilsson-Ehle Peter, Xu Ning: Influence of liver cancer on lipid and lipoprotein metabolism. Lipids in Health and Disease. 2006, 5 (4):
48.
go back to reference Motta M, Giugno I, Ruello P, et al: Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 2001, 92: 301-305.PubMed Motta M, Giugno I, Ruello P, et al: Lipoprotein (a) behaviour in patients with hepatocellular carcinoma. Minerva Med. 2001, 92: 301-305.PubMed
49.
go back to reference Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006, 130 (6): 1636-1642. 10.1053/j.gastro.2006.03.014.CrossRefPubMed Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006, 130 (6): 1636-1642. 10.1053/j.gastro.2006.03.014.CrossRefPubMed
50.
go back to reference Tessari P, Coracina A, Cosma A, Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009, 19 (4): 291-302. 10.1016/j.numecd.2008.12.015.CrossRefPubMed Tessari P, Coracina A, Cosma A, Tiengo A: Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009, 19 (4): 291-302. 10.1016/j.numecd.2008.12.015.CrossRefPubMed
Metadata
Title
Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: A cross-sectional study
Authors
Jinyan Zhao
Yunpeng Zhao
Hao Wang
Xing Gu
Jun Ji
Chunfang Gao
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Nutrition Journal / Issue 1/2011
Electronic ISSN: 1475-2891
DOI
https://doi.org/10.1186/1475-2891-10-49

Other articles of this Issue 1/2011

Nutrition Journal 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.